Skip to content

Serum Indoxyl Sulfate and p-Cresol Sulfate in Predicting Sarcopenia and Disability Risk in Hemodialysis Patients: A Multicenter Prospective Cohort Study

Serum Indoxyl Sulfate and p-Cresol Sulfate in Predicting Sarcopenia and Disability Risk in Hemodialysis Patients: A Multicenter Prospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107499
Enrollment
Unknown
Registered
2025-08-13
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

Hemodialysis Group:NA

Sponsors

?Shanghai Sixth People's Hospital?
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >18 years and <80 years; 2. Patients who have received maintenance hemodialysis for more than 3 months.

Exclusion criteria

Exclusion criteria: 1. Major limb loss or inability to walk independently; 2. Post-cardiac pacemaker implantation (contraindication for electrical impedance testing); 3. Severe heart failure (NYHA Class IV), decompensated cirrhosis, or respiratory failure; 4. Active malignant tumor; 5. Acute stroke, acute myocardial infarction, or malignant arrhythmia; 6. Severe infection (including sepsis); 7. Acute gastrointestinal bleeding; 8. Pre-existing sarcopenia or disability; 9. Other conditions deemed unsuitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
Sarcopenia;

Secondary

MeasureTime frame
Activities of daily living disability;

Countries

China

Contacts

Public ContactCheng Dongsheng

?Shanghai Sixth People's Hospital?

chengdongsheng@sjtu.edu.cn+86 189 3017 2266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026